Last reviewed · How we verify

DS-8201a — Competitive Intelligence Brief

DS-8201a (DS-8201a) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2-targeted antibody-drug conjugate. Area: Oncology.

phase 3 HER2-targeted antibody-drug conjugate HER2 (human epidermal growth factor receptor 2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

DS-8201a (DS-8201a) — Daiichi Sankyo Co., Ltd.. DS-8201a is an anti-HER2 antibody-drug conjugate that delivers a cytotoxic payload directly to HER2-expressing cancer cells.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DS-8201a TARGET DS-8201a Daiichi Sankyo Co., Ltd. phase 3 HER2-targeted antibody-drug conjugate HER2 (human epidermal growth factor receptor 2)
Trastuzumab deruxtecan-nxki Trastuzumab deruxtecan-nxki Memorial Sloan Kettering Cancer Center marketed HER2-targeted antibody-drug conjugate (ADC) HER2 (human epidermal growth factor receptor 2)
RC48-ADC RC48-ADC RemeGen Co., Ltd. phase 3 HER2-targeted antibody-drug conjugate HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2-targeted antibody-drug conjugate class)

  1. Daiichi Sankyo Co., Ltd. · 1 drug in this class
  2. RemeGen Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DS-8201a — Competitive Intelligence Brief. https://druglandscape.com/ci/ds-8201a. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: